ONCO Reverse Split on November 6: Why Your Shares Will Change 1-for-10

Onconetix, Inc. (Nasdaq: ONCO) is scheduled to implement a 1-for-10 reverse stock split effective at 12:01 a.m. Eastern Time on Friday, November 6, 2026. Every 10 existing ONCO shares will become one share; fractional shares will not be issued, and eligible fractional entitlements will be paid in cash. The ticker will remain ONCO, while the security's new CUSIP will be 68237Q500. This is the company's second 1-for-10 reverse split in 2026, taking the cumulative consolidation across the two actions to 1-for-100.

For shareholders checking their brokerage accounts, the immediate change is a lower share quantity and a mechanically adjusted per-share price. A reduced share count does not, by itself, mean an equivalent loss in investment value. The exact time at which an individual broker displays the adjusted position has not been independently confirmed.

What happens to ONCO shares on November 6?

Onconetix's October 26, 2026 Form 8-K says its Board determined on October 22 to implement an additional 1-for-10 reverse split. The filing states that the split is expected to become effective at 12:01 a.m. Eastern Time on November 6. Nasdaq's November 4 Corporate Actions Alert confirms the 1-for-10 action and the CUSIP change.

For Indian readers, 12:01 a.m. Eastern Time on November 6 converts to approximately 10:31 a.m. IST because the United States is on Eastern Standard Time by that date. Nasdaq's regular 9:30 a.m. Eastern Time opening corresponds to 8:00 p.m. IST on November 6. The effective time and the start of split-adjusted trading are separate milestones.

How many ONCO shares will you have after the reverse split?

Divide the number of ONCO shares held immediately before the November action by 10. Any whole-share entitlement will remain as shares; the fractional part will be settled in cash rather than issued as a fraction of an ONCO share.

For example, an investor holding 55 ONCO shares immediately before the split has an entitlement to 5.5 post-split shares. The investor receives 5 whole shares and cash for the remaining 0.5-share entitlement. The cash amount depends on the price specified by the company's settlement formula; it cannot be calculated from the share ratio alone.

These examples apply to holdings immediately before the November 6 action. They do not represent the number of shares held before the earlier May reverse split.

Why this is ONCO's second reverse split in 2026

Onconetix previously implemented a 1-for-10 reverse stock split effective May 21, 2026. The additional 1-for-10 action scheduled for November 6 brings the cumulative consolidation ratio to 1-for-100.

Consider an investor who held 100 shares immediately before the May split and retained the resulting shares until the November action. The May split would reduce the holding to 10 shares; the November split would reduce those 10 shares to 1 share. This is the mechanical result before considering any fractional-share cash settlements, purchases, sales or other position changes.

The two actions should not be confused with a single new 1-for-100 split on November 6. The November event itself is 1-for-10; 1-for-100 describes the combined effect of the May and November actions.

New CUSIP 68237Q500: Will the ONCO ticker change?

No. Onconetix's filing says the common stock is expected to continue trading on Nasdaq under the existing ticker symbol ONCO, with the new CUSIP 68237Q500. A ticker is the trading symbol used to identify a security on an exchange; a CUSIP is a separate security identifier used in market infrastructure and processing.

The new CUSIP does not mean shareholders are receiving shares in a different company. The corporate action consolidates Onconetix common stock. The company says brokerage-held positions will be automatically adjusted to reflect the reverse split.

Broker-specific processing for this exact ONCO corporate action on INDmoney, Vested, Interactive Brokers or other platforms has not been independently verified. The company's statement about automatic adjustment should not be interpreted as a guarantee of a particular display time or identical processing across brokers. If a position or transaction entry appears inconsistent after the action, shareholders should check the broker's corporate-action statement and contact the broker.

Fractional shares: how will the cash payment be calculated?

Onconetix's Form 8-K states that no fractional shares will be issued. A shareholder who would otherwise receive a fractional share will instead receive a cash payment, without interest.

The filing defines the payment as the fractional entitlement multiplied by the closing sale price per share on Nasdaq Capital Market at the close of business on the trading day immediately preceding the effective time, adjusted to give effect to the reverse split.

For a 55-share holding, the post-split entitlement is 5.5 shares: 5 whole shares plus a 0.5 fractional entitlement. The investor receives cash for that 0.5 fraction. The final amount depends on the applicable split-adjusted closing price; it should not be estimated using an unrelated market quote.

The filing also says proportional adjustments will be made, as applicable under their terms, to shares issuable upon exercise or conversion of outstanding equity awards, convertible preferred stock and warrants, along with relevant exercise or conversion prices.

Does a reverse split increase the value of ONCO shares?

A reverse split changes the share count and the per-share price mechanically. It does not, by itself, create business value or produce an investment gain.

This is a mechanical illustration, not a price forecast. It assumes no market movement and ignores transaction costs, taxes and fractional-share settlement. The actual ONCO market price can rise or fall after split-adjusted trading begins. A tenfold change in the quoted price that merely reflects a 1-for-10 consolidation is not, on its own, a tenfold investment return.

The company's filing estimates that outstanding common shares will decline from approximately 5.9 million to approximately 589,000 following the November action, before adjustments for fractional-share treatment. It also states that the number of authorized common shares will remain 250 million and the par value will remain $0.00001 per share.

What ONCO shareholders should check next

The announced effective date is November 6, and Nasdaq's Corporate Actions Alert confirms the ratio and new CUSIP. The company's October 26 filing said it expected to file the Certificate of Amendment with the Delaware Secretary of State on November 5. That statement was an expectation in the filing, not independent confirmation in that document that the state filing had been completed.

The filing directs shareholders with brokerage-held shares to contact their broker with account-specific questions. Other shareholders may contact the company's transfer agent, Continental Stock Transfer & Trust Company, at (212) 509-4000.

Frequently asked questions

What happens to my ONCO shares after the November 6 reverse split?

Every 10 existing shares will be combined into 1 share. The ticker is expected to remain ONCO, the new CUSIP is 68237Q500, and fractional entitlements will be paid in cash rather than issued as shares.

Why did my ONCO share quantity decrease?

The decrease reflects the 1-for-10 reverse split. The number of shares is divided by 10, with any fractional entitlement handled through cash in lieu.

What happens if I own 7 ONCO shares?

Seven shares produce a theoretical post-split entitlement of 0.7 share. Since the company will not issue fractional shares, that entitlement is settled in cash under the company's stated formula; it does not produce one whole ONCO share.

When will ONCO shares appear in my brokerage account?

The company says brokerage-held shares will be automatically adjusted, but its filing does not specify a universal processing or display time. Exact timing may vary by broker and has not been independently verified for INDmoney, Vested or Interactive Brokers.

Will ONCO change its ticker after the reverse split?

No ticker change has been announced. The company says the shares are expected to continue trading under ONCO, with the new CUSIP 68237Q500.

Is the November 2026 action ONCO's first reverse split this year?

No. Onconetix implemented a 1-for-10 reverse split effective May 21, 2026. The November 6 action is another 1-for-10 split, making the cumulative effect of the two actions 1-for-100.

Does a 1-for-10 reverse split mean my investment becomes worth ten times more?

No. The share quantity is divided by 10 and the per-share price is mechanically adjusted. The split itself does not create an equivalent gain; the market price can move independently after trading resumes.

For ONCO shareholders, the practical calculation is simple: divide the pre-November 6 share count by 10, retain the whole-share entitlement and expect cash for any fraction. The ticker remains ONCO, the new CUSIP is 68237Q500, and the precise time a broker displays the adjusted position is not specified by the company.